|
1
|
Gusyatiner O and Hegi ME: Glioma
epigenetics: From ubclassification to novel treatment options.
Semin Cancer Biol. 51:50–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aldape K, Brindle KM, Chesler L, Chopra R,
Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland
EC, et al: Challenges to curing primary brain tumours. Nat Rev Clin
Oncol. 16:509–520. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lapointe S, Perry A and Butowski NA:
Primary brain tumours in adults. Lancet. 392:432–446. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Post-transcriptional processing generates
a diversity of 5′-modified long and short RNAs. Nature.
457:1028–1032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arun G, Diermeier SD and Spector DL:
Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol
Med. 24:257–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and
Ma W: ceRNA in cancer: Possible functions and clinical
implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abdollahzadeh R, Daraei A, Mansoori Y,
Sepahvand M, Amoli MM and Tavakkoly-Bazzaz J: Competing endogenous
RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A
new look at hallmarks of breast cancer. J Cell Physiol.
234:10080–10100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qu S, Liu Z, Yang X, Zhou J, Yu H, Zhang R
and Li H: The emerging functions and roles of circular RNAs in
cancer. Cancer Lett. 414:301–309. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang KC and Chang HY: Molecular mechanisms
of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng Z, Liu C and Wu M: New insights into
long noncoding RNAs and their roles in glioma. Mol Cancer.
17:612018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin C and Yang L: Long Noncoding RNA in
cancer: Wiring signaling circuitry. Trends Cell Biol. 28:287–301.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kopp F and Mendell JT: Functional
classification and experimental dissection of long noncoding RNAs.
Cell. 172:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang Z, Li C, Kang B, Gao G and Zhang Z:
GEPIA: A web server for cancer and normal gene expression profiling
and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peters L and Meister G: Argonaute
proteins: Mediators of RNA silencing. Mol Cell. 26:611–623. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Research Council: Guide for the
Care and Use of Laboratory Animals. The National Academies Press;
Washington, DC: 1996
|
|
21
|
Alavi MV: Targeted OMA1 therapies for
cancer. Int J Cancer. 145:2330–2341. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thu HE, Hussain Z, Mohamed IN and Shuid
AN: Eurycoma longifolia, a potential phytomedicine for the
treatment of cancer: Evidence of p53-mediated apoptosis in
cancerous cells. Curr Drug Targets. 19:1109–1126. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jung E, Alfonso J, Osswald M, Monyer H,
Wick W and Winkler F: Emerging intersections between neuroscience
and glioma biology. Nat Neurosci. 22:1951–1960. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rynkeviciene R, Simiene J, Strainiene E,
Stankevicius V, Usinskiene J, Kaubriene EM, Meskinyte I, Cicenas J
and Suziedelis K: Non-coding RNAs in glioma. Cancers (Basel).
11:172018. View Article : Google Scholar
|
|
25
|
Zheng Y, Xie J, Xu X, Yang X, Zhou Y, Yao
Q and Xiong Y: lncRNA DDX11-AS1 exerts oncogenic roles in glioma
through regulating miR-499b-5p/RWDD4 axis. Onco Targets Ther.
14:157–164. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei Y, Zhou K, Wang C, Du X, Xiao Q and
Chen C: Adsorption of miR-218 by lncRNA HOTAIR regulates PDE7A and
affects glioma cell proliferation, invasion, and apoptosis. Int J
Clin Exp Pathol. 13:2973–2983. 2020.PubMed/NCBI
|
|
27
|
Wu YJ, Yang QS, Chen H, Wang JT, Wang WB
and Zhou L: Long non-coding RNA CASC19 promotes glioma progression
by modulating the miR-454-3p/RAB5A axis and is associated with
unfavorable MRI features. Oncol Rep. 45:728–737. 2021. View Article : Google Scholar
|
|
28
|
Wang H, Lu B, Ren S, Wu F, Wang X, Yan C
and Wang Z: Long noncoding RNA LINC01116 contributes to gefitinib
resistance in non-small cell lung cancer through regulating IFI44.
Mol Ther Nucleic Acids. 19:218–227. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu HB, Chen Q and Ding SQ: lncRNA
LINC01116 competes with miR-145 for the regulation of ESR1
expression in breast cancer. Eur Rev Med Pharmacol Sci.
22:1987–1993. 2018.PubMed/NCBI
|
|
30
|
Chen J, Yuan ZH, Hou XH, Shi MH and Jiang
R: LINC01116 promotes the proliferation and inhibits the apoptosis
of gastric cancer cells. Eur Rev Med Pharmacol Sci. 24:1807–1814.
2020.PubMed/NCBI
|
|
31
|
Xing H, Sun H and Du W: LINC01116
accelerates nasopharyngeal carcinoma progression based on its
enhancement on MYC transcription activity. Cancer Med. 9:267–277.
2020. View Article : Google Scholar
|
|
32
|
Zhang ZF, Xu HH, Hu WH, Hu TY and Wang XB:
LINC01116 promotes proliferation, invasion and migration of
osteosarcoma cells by silencing p53 and EZH2. Eur Rev Med Pharmacol
Sci. 23:6813–6823. 2019.PubMed/NCBI
|
|
33
|
Wu J, Chen Z, Zhang L, Cao J, Li X, Gong
Z, Bo H, Zhang S and He D: Knockdown of LINC01116 inhibits cell
migration and invasion in head and neck squamous cell carcinoma
through epithelial-mesenchymal transition pathway. J Cell Biochem.
121:867–875. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Z, Tao Q, Qiao B and Zhang L:
Silencing of LINC01116 suppresses the development of oral squamous
cell carcinoma by up-regulating microRNA-136 to inhibit FN1. Cancer
Manag Res. 11:6043–6059. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ye J, Zhu J, Chen H, Qian J, Zhang L, Wan
Z, Chen F, Sun S, Li W and Luo C: A novel lncRNA-LINC01116
regulates tumorigenesis of glioma by targeting VEGFA. Int J Cancer.
146:248–261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fang YN, Huang ZL, Li H, Tan WB, Zhang QG,
Wang L and Wu JL: LINC01116 promotes the progression of epithelial
ovarian cancer via regulating cell apoptosis. Eur Rev Med Pharmacol
Sci. 22:5127–5133. 2018.PubMed/NCBI
|
|
37
|
Zhang B, Yu L, Han N, Hu Z, Wang S, Ding L
and Jiang J: LINC01116 targets miR-520a-3p and affects IL6R to
promote the proliferation and migration of osteosarcoma cells
through the Jak-stat signaling pathway. Biomed Pharmacother.
107:270–282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and
p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tiwari B, Jones AE and Abrams JM:
Transposons, p53 and genome security. Trends Genet. 34:846–855.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hafner A, Bulyk ML, Jambhekar A and Lahav
G: The multiple mechanisms that regulate p53 activity and cell
fate. Nat Rev Mol Cell Biol. 20:199–210. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stiewe T and Haran TE: How mutations shape
p53 interactions with the genome to promote tumorigenesis and drug
resistance. Drug Resist Updat. 38:27–43. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Oliner JD, Saiki AY and Caenepeel S: The
role of MDM2 amplification and overexpression in tumorigenesis.
Cold Spring Harb Perspect Med. 6:a0263362016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu X, Bayle JH, Olson D and Levine AJ: The
p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126–1132.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hernandez-Monge J, Rousset-Roman AB,
Medina-Medina I and Olivares-Illana V: Dual function of MDM2 and
MDMX toward the tumor suppressors p53 and RB. Genes Cancer.
7:278–287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao J, Li L, Han ZY, Wang ZX and Qin LX:
Long noncoding RNAs, emerging and versatile regulators of
tumor-induced angiogenesis. Am J Cancer Res. 9:1367–1381.
2019.PubMed/NCBI
|
|
46
|
Adams BD, Parsons C, Walker L, Zhang WC
and Slack FJ: Targeting noncoding RNAs in disease. J Clin Invest.
127:761–771. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bracken CP, Scott HS and Goodall GJ: A
network-biology perspective of microRNA function and dysfunction in
cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Anfossi S, Babayan A, Pantel K and Calin
GA: Clinical utility of circulating non-coding RNAs - an update.
Nat Rev Clin Oncol. 15:541–563. 2018. View Article : Google Scholar : PubMed/NCBI
|
